CN112105638A - C3结合剂及其使用方法 - Google Patents

C3结合剂及其使用方法 Download PDF

Info

Publication number
CN112105638A
CN112105638A CN201980027315.6A CN201980027315A CN112105638A CN 112105638 A CN112105638 A CN 112105638A CN 201980027315 A CN201980027315 A CN 201980027315A CN 112105638 A CN112105638 A CN 112105638A
Authority
CN
China
Prior art keywords
seq
heavy chain
light chain
variable region
binding agent
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Pending
Application number
CN201980027315.6A
Other languages
English (en)
Chinese (zh)
Inventor
D·Y·M·杜威
刘中豪
汤捷
王雁
尹轶苑
翟文武
J·M·希格比
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
NGM Biopharmaceuticals Inc
Original Assignee
NGM Biopharmaceuticals Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by NGM Biopharmaceuticals Inc filed Critical NGM Biopharmaceuticals Inc
Publication of CN112105638A publication Critical patent/CN112105638A/zh
Pending legal-status Critical Current

Links

Images

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P27/00—Drugs for disorders of the senses
    • A61P27/02—Ophthalmic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/20—Immunoglobulins specific features characterized by taxonomic origin
    • C07K2317/24—Immunoglobulins specific features characterized by taxonomic origin containing regions, domains or residues from different species, e.g. chimeric, humanized or veneered
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/30—Immunoglobulins specific features characterized by aspects of specificity or valency
    • C07K2317/31—Immunoglobulins specific features characterized by aspects of specificity or valency multispecific
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/30—Immunoglobulins specific features characterized by aspects of specificity or valency
    • C07K2317/33—Crossreactivity, e.g. for species or epitope, or lack of said crossreactivity
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/56—Immunoglobulins specific features characterized by immunoglobulin fragments variable (Fv) region, i.e. VH and/or VL
    • C07K2317/565—Complementarity determining region [CDR]
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/60—Immunoglobulins specific features characterized by non-natural combinations of immunoglobulin fragments
    • C07K2317/62—Immunoglobulins specific features characterized by non-natural combinations of immunoglobulin fragments comprising only variable region components
    • C07K2317/622—Single chain antibody (scFv)
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/60—Immunoglobulins specific features characterized by non-natural combinations of immunoglobulin fragments
    • C07K2317/62—Immunoglobulins specific features characterized by non-natural combinations of immunoglobulin fragments comprising only variable region components
    • C07K2317/624—Disulfide-stabilized antibody (dsFv)
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
    • C07K2317/76—Antagonist effect on antigen, e.g. neutralization or inhibition of binding
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/90—Immunoglobulins specific features characterized by (pharmaco)kinetic aspects or by stability of the immunoglobulin
    • C07K2317/92—Affinity (KD), association rate (Ka), dissociation rate (Kd) or EC50 value
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/90—Immunoglobulins specific features characterized by (pharmaco)kinetic aspects or by stability of the immunoglobulin
    • C07K2317/94—Stability, e.g. half-life, pH, temperature or enzyme-resistance

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Immunology (AREA)
  • Biochemistry (AREA)
  • Biophysics (AREA)
  • Genetics & Genomics (AREA)
  • Molecular Biology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Veterinary Medicine (AREA)
  • Ophthalmology & Optometry (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Engineering & Computer Science (AREA)
  • Peptides Or Proteins (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Preparation Of Compounds By Using Micro-Organisms (AREA)
  • Medicinal Preparation (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
CN201980027315.6A 2018-04-03 2019-04-01 C3结合剂及其使用方法 Pending CN112105638A (zh)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US201862652253P 2018-04-03 2018-04-03
US62/652,253 2018-04-03
PCT/US2019/025123 WO2019195136A1 (en) 2018-04-03 2019-04-01 C3-binding agents and methods of use thereof

Publications (1)

Publication Number Publication Date
CN112105638A true CN112105638A (zh) 2020-12-18

Family

ID=66630340

Family Applications (1)

Application Number Title Priority Date Filing Date
CN201980027315.6A Pending CN112105638A (zh) 2018-04-03 2019-04-01 C3结合剂及其使用方法

Country Status (18)

Country Link
US (3) US11136381B2 (https=)
EP (1) EP3790897A1 (https=)
JP (2) JP7477457B2 (https=)
KR (1) KR20200138290A (https=)
CN (1) CN112105638A (https=)
AR (1) AR117565A1 (https=)
AU (1) AU2019248557A1 (https=)
BR (1) BR112020019907A2 (https=)
CA (1) CA3093356A1 (https=)
CL (2) CL2020002522A1 (https=)
CO (1) CO2020013468A2 (https=)
IL (1) IL277404A (https=)
MX (1) MX2020010323A (https=)
PE (1) PE20212132A1 (https=)
PH (1) PH12020500664A1 (https=)
SG (1) SG11202008897SA (https=)
TW (1) TWI833742B (https=)
WO (1) WO2019195136A1 (https=)

Families Citing this family (8)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2019195136A1 (en) 2018-04-03 2019-10-10 Ngm Biopharmaceuticals, Inc. C3-binding agents and methods of use thereof
WO2021226442A2 (en) * 2020-05-08 2021-11-11 Ngm Biopharmaceuticals, Inc. Therapeutic uses of c3-binding agents
US20230381269A1 (en) * 2020-09-21 2023-11-30 Apellis Pharmaceuticals, Inc. Methods of treating eye disorders
CN116848136A (zh) * 2021-02-12 2023-10-03 勃林格殷格翰国际有限公司 补体c3抗原结合蛋白
IL313655A (en) 2021-12-22 2024-08-01 Boehringer Ingelheim Int Anti-C3 antibodies and their antigen-binding fragments and their uses for the treatment of eyes or eye diseases
WO2024086555A1 (en) 2022-10-17 2024-04-25 Ngm Biopharmaceuticals, Inc. Uses of anti-c3 antibodies
CN117447601B (zh) * 2023-12-22 2024-03-08 北京索莱宝科技有限公司 猪IgM的抗体、抗体组合物及其应用
WO2025149667A1 (en) 2024-01-12 2025-07-17 Pheon Therapeutics Ltd Antibody drug conjugates and uses thereof

Citations (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2004031240A1 (en) * 2002-10-04 2004-04-15 Stichting Sanquin Bloedvoorziening Monoclonal antibody anti-c3-2 directed against the third component of complement (c3) and its use in methods to inhibit complement activation
WO2010136311A2 (en) * 2009-05-06 2010-12-02 Novartis Ag Compositions and methods for antibodies targeting complement protein c3b
RU2630647C1 (ru) * 2016-05-27 2017-09-11 Федеральное государственное унитарное предприятие "Государственный научно-исследовательский институт особо чистых биопрепаратов" Федерального медико-биологического агентства ГУМАНИЗИРОВАННОЕ АНТИТЕЛО К КОНФОРМАЦИОННОМУ ЭПИТОПУ С3 КОМПОНЕНТА КОМПЛЕМЕНТА ЧЕЛОВЕКА, ПОСЛЕДОВАТЕЛЬНОСТЬ ДНК (ВАРИАНТЫ), ЭКСПРЕССИОННЫЙ ВЕКТОР, СОДЕРЖАЩИЙ ПОСЛЕДОВАТЕЛЬНОСТЬ ДНК (ВАРИАНТЫ), И ШТАММ КЛЕТОК ЯИЧНИКОВ КИТАЙСКОГО ХОМЯЧКА CHO-humC34-ПРОДУЦЕНТ ДАННОГО ГУМАНИЗИРОВАННОГО АНТИТЕЛА
CN107249318A (zh) * 2014-12-10 2017-10-13 明尼苏达大学董事会 用于治疗疾病的遗传修饰的细胞、组织和器官

Family Cites Families (23)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
MXPA01002580A (es) * 1998-09-10 2002-04-08 Univ Virginia Anticuerpos para c3b(1) para el suministro de agentes de diagnostico y terapeuticos para celulas cancerosas.
US7816497B2 (en) 2002-10-30 2010-10-19 University Of Kentucky Compositions and methods for inhibiting drusen complement components C3a and C5a for the treatment of age-related macular degeneration
WO2004041867A2 (en) * 2002-11-08 2004-05-21 Ablynx N.V. Camelidae antibodies against imminoglobulin e and use thereof for the treatment of allergic disorders
US20090004183A1 (en) 2004-07-23 2009-01-01 Taylor Ronald P Compositions and Methods for Regulating the Alternative Pathway of Complement
WO2006083533A2 (en) 2005-01-14 2006-08-10 The Regents Of The University Of California Compositions and methods for inhibiting drusen formation and for diagnosing or treating drusen-related disorders
US8168584B2 (en) 2005-10-08 2012-05-01 Potentia Pharmaceuticals, Inc. Methods of treating age-related macular degeneration by compstatin and analogs thereof
EP3299027A1 (en) 2005-11-04 2018-03-28 Genentech, Inc. Use of complement pathway inhibitors to treat ocular diseases
PL2148691T3 (pl) 2007-02-05 2015-12-31 Apellis Pharmaceuticals Inc Analogi kompstatyny do stosowania w leczeniu stanów zapalnych układu oddechowego
US9745367B2 (en) 2007-03-23 2017-08-29 Novelmed Theraputics, Inc. Alternative pathway specific antibodies for treating arthritis
US8192742B2 (en) 2007-03-23 2012-06-05 NovelMed Therapeutics Method of inhibiting complement activation with human anti-factor C3 antibodies and use thereof
BRPI0812767A2 (pt) 2007-06-07 2014-12-02 Genentech Inc Anticorpos para c3b e métodos para prevenção e tratamento de distúrbios associados ao complemento
RU2548807C2 (ru) 2009-05-20 2015-04-20 Торэй Индастриз, Инк. Пептиды, проникающие в клетку
US9291622B2 (en) 2009-05-21 2016-03-22 Apellis Pharmaceuticals, Inc. Complement assays and uses thereof
US20130177567A1 (en) 2010-05-18 2013-07-11 Sydansk Universitet Novel c3c epitope, antibodies binding thereto, and use thereof
US9815890B2 (en) 2010-06-22 2017-11-14 The Regents Of The University Of Colorado, A Body Corporate Antibodies to the C3d fragment of complement component 3
US9243060B2 (en) 2012-04-03 2016-01-26 Novelmed Therapeutics, Inc. Humanized anti-factor C3b antibodies and uses thereof
WO2015099838A2 (en) 2013-12-24 2015-07-02 Novelmed Therapeutics, Inc. Compositions and methods of treating ocular diseases
SG10202003996YA (en) 2014-05-05 2020-06-29 Regeneron Pharma Humanized c5 and c3 animals
US10815276B2 (en) 2014-05-21 2020-10-27 Entrada Therapeutics, Inc. Cell penetrating peptides and methods of making and using thereof
US20180346531A1 (en) 2015-09-15 2018-12-06 Regents Of The University Of California Compositions and methods for delivering biotherapeutics
EP3359555B1 (en) 2015-10-07 2023-12-20 Apellis Pharmaceuticals, Inc. Dosing regimens
EP3654941A1 (en) 2017-07-17 2020-05-27 Keith Roizman Topical delivery of therapeutic agents comprising cell-penetrating peptides for use for the treatment of age-related macular degeneration and other eye diseases
WO2019195136A1 (en) 2018-04-03 2019-10-10 Ngm Biopharmaceuticals, Inc. C3-binding agents and methods of use thereof

Patent Citations (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2004031240A1 (en) * 2002-10-04 2004-04-15 Stichting Sanquin Bloedvoorziening Monoclonal antibody anti-c3-2 directed against the third component of complement (c3) and its use in methods to inhibit complement activation
WO2010136311A2 (en) * 2009-05-06 2010-12-02 Novartis Ag Compositions and methods for antibodies targeting complement protein c3b
CN107249318A (zh) * 2014-12-10 2017-10-13 明尼苏达大学董事会 用于治疗疾病的遗传修饰的细胞、组织和器官
RU2630647C1 (ru) * 2016-05-27 2017-09-11 Федеральное государственное унитарное предприятие "Государственный научно-исследовательский институт особо чистых биопрепаратов" Федерального медико-биологического агентства ГУМАНИЗИРОВАННОЕ АНТИТЕЛО К КОНФОРМАЦИОННОМУ ЭПИТОПУ С3 КОМПОНЕНТА КОМПЛЕМЕНТА ЧЕЛОВЕКА, ПОСЛЕДОВАТЕЛЬНОСТЬ ДНК (ВАРИАНТЫ), ЭКСПРЕССИОННЫЙ ВЕКТОР, СОДЕРЖАЩИЙ ПОСЛЕДОВАТЕЛЬНОСТЬ ДНК (ВАРИАНТЫ), И ШТАММ КЛЕТОК ЯИЧНИКОВ КИТАЙСКОГО ХОМЯЧКА CHO-humC34-ПРОДУЦЕНТ ДАННОГО ГУМАНИЗИРОВАННОГО АНТИТЕЛА

Non-Patent Citations (2)

* Cited by examiner, † Cited by third party
Title
DIMITRIOS MASTELLOS等: "Novel monoclonal antibodies against mouse C3 interfering with complement activation: description of fine specificity and applications to various immunoassays", MOLECULAR IMMUNOLOGY, vol. 40, no. 16, 31 March 2004 (2004-03-31), pages 1213 - 1221, XP002516656, DOI: 10.1016/j.molimm.2003.10.019 *
漆晓玲等: "补体C3 与四种自身抗体在诊断SLE 中的意义", 中国现代医生, vol. 47, no. 30, 28 October 2009 (2009-10-28), pages 96 - 97 *

Also Published As

Publication number Publication date
JP7477457B2 (ja) 2024-05-01
EP3790897A1 (en) 2021-03-17
TW202003559A (zh) 2020-01-16
RU2020135712A (ru) 2022-05-04
JP2024056851A (ja) 2024-04-23
US20230382985A1 (en) 2023-11-30
JP2021520195A (ja) 2021-08-19
US20190322730A1 (en) 2019-10-24
KR20200138290A (ko) 2020-12-09
SG11202008897SA (en) 2020-10-29
WO2019195136A1 (en) 2019-10-10
US20220119508A1 (en) 2022-04-21
CL2020002522A1 (es) 2021-02-26
MX2020010323A (es) 2021-01-08
PE20212132A1 (es) 2021-11-05
CA3093356A1 (en) 2019-10-10
AR117565A1 (es) 2021-08-18
US11136381B2 (en) 2021-10-05
BR112020019907A2 (pt) 2021-01-05
TWI833742B (zh) 2024-03-01
IL277404A (en) 2020-11-30
AU2019248557A1 (en) 2020-09-24
CL2021002039A1 (es) 2022-04-01
US11767359B2 (en) 2023-09-26
CO2020013468A2 (es) 2020-11-10
PH12020500664A1 (en) 2021-06-07

Similar Documents

Publication Publication Date Title
US11767359B2 (en) C3-binding agents and methods of use thereof
JP7811315B2 (ja) 補体関連疾患のための融合タンパク質構築物
WO2018161872A1 (zh) 抗b7-h3抗体、其抗原结合片段及其医药用途
CN109415435B (zh) 新型抗体形式
JP7610515B2 (ja) ヒト化抗Ｎ短縮型アミロイドβモノクローナル抗体
JP2024518724A (ja) 抗ｍａｓｐ２抗体、その抗原結合断片および医薬用途
US20220251241A1 (en) Htra1-binding agents and methods of use thereof
CN117858721A (zh) 用于治疗α-突触核蛋白病的抗体
WO2021226442A2 (en) Therapeutic uses of c3-binding agents
US20250270328A1 (en) Klrb1 binding agents and methods of use thereof
RU2802307C2 (ru) C3-связывающие агенты и способы их применения
WO2023241389A1 (zh) 针对tfpi的单克隆抗体及其用途
JP2024544924A (ja) トランスサイレチン（ｔｔｒ）単量体結合抗体
WO2026012421A1 (zh) 抗N3pGlu淀粉样蛋白β抗体及其用途
TW201628648A (zh) 纖維變性疾病之治療
HK40123789A (zh) 优化的抗tl1a抗体
CN117756936A (zh) 一种Axl拮抗抗体或抗原结合片段
HK40042163B (zh) 优化的抗tl1a抗体

Legal Events

Date Code Title Description
PB01 Publication
PB01 Publication
SE01 Entry into force of request for substantive examination
SE01 Entry into force of request for substantive examination
WD01 Invention patent application deemed withdrawn after publication
WD01 Invention patent application deemed withdrawn after publication

Application publication date: 20201218